Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eribulin + carboplatin with trastuzumab + pertuzumab as neoadjuvant therapy for HER2-positive early or locally advanced breast cancer
ChiCTR2500095130Phase 2Not yet recruiting
- Sponsor
- Sichuan Cancer Hospital
- Start
- Jan 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of eribulin, carboplatin, trastuzumab and pertuzumab in breast cancer, sponsored by Sichuan Cancer Hospital. Primary endpoint: Pathological complete response rate. Planned start Jan 2025; status: not yet recruiting.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR2500095130.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500095130.